The animal health spinoff is the second major industry player to go public, following Zoetis' successful offering.
Eli Lilly reported a quarterly loss of $260 million and announced plans for an IPO of Elanco by the end of 2018.
The spun-off materials science company had to build out most functions from scratch but has seen surprising early business results.
MetLife's "bold move" could set a precedent for other "systemically important" insurers seeking to avoid higher capital requirements.
The proceeds of the spin-off will be used to “increase growth and drive profitability through ... disciplined capital allocation," the Dutch company said.
A Bloomberg columnist proposes an interesting endgame for Yahoo's latest move to capitalize on its Alibaba share holdings.
